Shofu Inc. Overview
SHOFU is Japan's oldest and one of its most diversified dental consumables manufacturers, tracing its roots to the country's first high-quality porcelain artificial teeth in 1922. The company spans the full restorative workflow — artificial teeth, abrasives and polishing systems, composite resins, adhesives, cements, ceramics, CAD/CAM blocks and discs, and clinical equipment such as intraoral photography cameras — serving dental clinics and dental laboratories through dealers in Japan and wholly owned sales subsidiaries in the US, Germany, the UK, China, Singapore, India, Brazil and, since 2026, the Middle East. Its signature intellectual property is Giomer/S-PRG bioactive filler technology, embedded in the BEAUTIFIL composite family. With a debt-free balance sheet, an equity ratio above 80%, and overseas sales near 59% of revenue, SHOFU is a mid-cap niche consolidator that has set itself a ¥50bn sales target for FY2028 and an aspirational ¥250bn, 20%-margin "global top-10" goal for 2040.
Company's own description
The Yuho FY2026 describes the group as comprising SHOFU INC., 18 consolidated subsidiaries, one unconsolidated subsidiary, one equity-method affiliate (Sun Medical Co., Ltd.) and one "other affiliated company" (Mitsui Chemicals). The group operates as a comprehensive manufacturer of dental materials and equipment, with two smaller adjacent businesses: nail-care products and industrial abrasives. The Yuho identifies the main dental product families as artificial teeth, abrasives (grinding and polishing), dental metals, chemical products (restoratives, adhesives, CAD/CAM materials), cements, and machinery and instruments.
The corporate philosophy is to contribute to global dental care through creative corporate activity. The corporate message used in investor materials translates as "supporting the ability to chew, smile and live."
Business model and revenue model
| Revenue type | Share of revenue | Comment |
|---|---|---|
| Product sales (consumables) | Large majority (precise split n.d.) | Restoratives, abrasives, artificial teeth, cements, CAD/CAM materials |
| Product sales (equipment) | Minor share (n.d.) | Intraoral cameras, laboratory equipment, curing devices |
| Repair / after-sales service | Minor (n.d.) | Equipment repair services; order backlog ¥494m at FY2026 end, all dental |
| Subscription / licensing | Not material | CAD software "Go2 dental" is updated periodically; licensing revenue not separately disclosed |
SHOFU runs a vertically integrated, product-sale business model. It does R&D in Kyoto (and at subsidiaries in Germany and the UK), manufactures in Japan (Kyoto, Shiga, Kumiyama), China (Shanghai, Changzhou), Vietnam, Germany and the UK, and sells primarily through dental dealers (domestically and in most export markets), supported by its own sales subsidiaries and a "academic network" of key opinion leaders.
Revenue recognition is at delivery to customers (domestic sales recognised at shipment under the alternative treatment; exports recognised at shipment/loading under trade terms), per the Yuho FY2026 accounting policies. No single customer exceeds 10% of consolidated sales.
Value-chain position
SHOFU sits in the manufacturer tier of the dental value chain. It sources chemical and ceramic raw materials, adds value through proprietary filler chemistry, ceramics processing and precision abrasive manufacture, and relies on distributors (dental dealers) to reach end users. In Japan it is also a key supplier into the national health insurance-reimbursed restorative market, notably CAD/CAM crowns made from resin-based blocks and PEEK.
Customer types and end-markets
Dental clinics (chairside): composites (BEAUTIFIL), adhesives (BeautiBond), cements, polishing systems, preventive products, orthodontic materials, intraoral cameras.
Dental laboratories (labside): artificial teeth, porcelain and stains (Vintage line), indirect composites (Ceramage), CAD/CAM blocks and discs, laboratory abrasives.
Dental dealers: primary channel in Japan, North America and Europe.
Nail salons and consumers: gel and acrylic nail systems (Nail Labo).
Industrial users: rubber-bonded abrasives for moulds, ceramics and plastics (SHOFU Products Kyoto).
Independent characterisation
SHOFU is best understood as a restorative-materials specialist with a strong legacy franchise in prosthetics (artificial teeth, abrasives) that is pivoting toward digital dentistry (CAD/CAM materials, software, intraoral imaging) and overseas growth. Its competitive edge is chemistry-led differentiation (Giomer/S-PRG bioactive fillers) rather than scale. The economics show high gross margins (~59%) but SG&A-heavy cost structures (~46% of sales), typical of a mid-sized dental consumables player that must maintain dealer support, clinical education and multi-country regulatory compliance without the scale advantages of Dentsply Sirona or Envista. The Mitsui Chemicals capital tie-up (20.11%) gives SHOFU a strategic anchor shareholder that also owns competitor-cum-partner businesses (Kulzer and Sun Medical).
Strategy
Stated strategy (Yuho FY2026, paraphrased)
Management philosophy: contribute to global dental care through creative corporate activity; pursue quantitative growth while prioritising quality; anticipate change and take on challenges.
Long-term vision "Vision10" (announced December 2025): become a global top-10 dental company by 2040, positioned as a leading company in digital dentistry and oral care. Targets for 2040: group net sales of ¥250bn and operating profit of ¥50bn (20% margin) — roughly 5x sales and 6.6x operating income versus FY2028 plan levels.
Three strategic pillars of Vision10: (1) strengthen the core restorative-materials franchise; (2) accelerate global and digital initiatives in growth areas (digital dentistry, prevention, orthodontics); (3) explore new domains (periodontal disease, sleep dentistry, diagnostic devices) via organic growth, alliances and M&A.
Fifth Medium-Term Management Plan (FY2025–FY2028)
| Target | FY2028 goal |
|---|---|
| Group net sales | ¥50.1bn (Japan ¥18.7bn; overseas ¥31.4bn) |
| Operating profit | ¥7.5bn (15% margin) |
| ROE | 13.5% (from 9.5% in FY2024) |
| Production-capacity capex | ¥9bn (Kyoto head office plant ¥3.7bn; domestic bases ¥3.1bn; overseas bases ¥2.2bn) |
| Cross-shareholdings | Reduce to ~10% of net assets (from ~20% in FY2024; 16.3% at FY2026) |
| Shareholder return | Consolidated payout ≥40% and DOE ≥3.0% |
The "¥50 billion Vision" dates from 2012 and has been deferred several times (originally 2022, then 2027, now FY2028), per the company's integrated report.
FY2026 priority issues (Yuho): region-specific new products; sales network and bases; domestic and overseas academic networks; relocation of production and expansion of overseas manufacturing; global talent; funding for higher capital needs; M&A (business/technology alliances and acquisitions); group governance; the Mitsui Chemicals / Sun Medical alliance; and sustainability management.
Initiatives in the last 24 months
| Initiative | Status / detail |
|---|---|
| Kyoto head-office plant rebuild ("SMILE FACTORY TAKUMI") | Phase 1 completed Mar 2026; full completion Aug 2028; budget ¥4,091m |
| Shiga Shofu new plant | ¥1,370m, loan-financed; completion Dec 2026 |
| Changzhou (China) manufacturing | Established Apr 2024 |
| Middle East & Africa sales subsidiary | Consolidated Q1 FY2027 |
| Implant business integration | SHOFU BIOFIX absorbed 1 Oct 2026 to strengthen digital-dentistry system proposals |
| US entity rationalisation | Smart Dentistry Solutions merged into SHOFU Dental Corp., Jan 2026 |
| Capital-efficiency programme (May 2024, updated May 2025) | ROE target 13.5%; liquidity measures (stock split Oct 2024); takeover defence removed |
| Cross-shareholding unwinding | 4 listed holdings sold in FY2026 (¥1,124m); further ¥1,124m gain in Q1 FY2027; proceeds to capex and special dividends |
| Human capital | Global, DX and next-generation leadership talent pipelines; consolidated-linked employee bonus from summer 2026 |
| Sustainability | Scope 1+2 −27% by FY2030 vs FY2021; carbon neutral by 2050 |
Near-term guidance (FY2027, issued 13 May 2026; unchanged at Q1)
| Metric | H1 FY2027 guidance | FY2027 guidance | YoY (FY) |
|---|---|---|---|
| Net sales (JPY m) | 20,669 | 42,958 | +7.4% |
| Operating profit (JPY m) | 2,949 | 6,003 | +14.9% |
| Ordinary profit (JPY m) | 2,861 | 5,890 | +0.5% |
| Net profit (JPY m) | 2,552 | 4,756 | -2.7% |
| EPS (JPY) | 71.73 | 133.66 | — |
| DPS (JPY) | 39 (incl. 12 special) | 67 | +11.7% |
Products & Services
Pricing is not publicly disclosed at group level; most dental consumables are sold through dealers at list prices, and in Japan many restorative products are priced against national health insurance reimbursement schedules. Launch dates below are from the Yuho FY2026 R&D section where stated; otherwise "n.d.".
Dental-related Business — Chairside restoratives and adhesives
| Product | Description / capabilities | Target customer | Latest version / date |
|---|---|---|---|
| BEAUTIFIL family (incl. BEAUTIFIL II, BEAUTIFIL Flow Plus) | Giomer composites containing S-PRG filler that release and recharge fluoride and other ions | General dentists | Ongoing line; flagship franchise |
| BEAUTIFIL II LS | Low-shrinkage composite resin | Dentists (Europe launch) | Launched in Europe, August 2025 |
| BeautiBond adhesive family | Self-etch bonding agents | Dentists | — |
| SHOFU Etchant | 40% phosphoric acid gel for selective enamel etching, successor to Imperva Bond Etching Gel | Dentists | August 2025 |
| Cements (incl. resin and glass-ionomer types) | Luting and restorative cements; management cites cements as a priority export category | Dentists | — |
Dental-related Business — CAD/CAM and digital
| Product | Description / capabilities | Target customer | Latest version / date |
|---|---|---|---|
| SHOFU Disk ZR Lucent Supra | Zirconia ceramic disc for milling | Dental labs | Key growth driver FY2026 (Japan and Europe) |
| SHOFU Block HC Super Hard | Hybrid resin block for milling crowns | Labs / clinics (Japan insurance-reimbursed CAD/CAM crowns) | Key growth driver FY2026 |
| SHOFU Block PEEK | PEEK block for milling crowns | Labs / clinics (Japan) | Key growth driver FY2026 |
| Go2 dental | CAD software | Labs | Version updates August and December 2025 |
| EyeSpecial digital camera series | Intraoral / clinical photography cameras | Dentists | Cited as a driver of FY2025 domestic sales (secondary source) |
| S-WAVE CAD/CAM Processing Center | Contract milling service in Kumiyama, Kyoto | Dental labs (Japan) | Operating since 2014 |
| Digital Dental Services GmbH | Digital processing and sales service in Germany | Labs (Europe) | Subsidiary of Merz Dental |
Dental-related Business — Laboratory materials and prosthetics
| Product | Description / capabilities | Target customer | Latest version / date |
|---|---|---|---|
| Artificial teeth (resin and porcelain) | The company's founding product category; Merz Dental supplies European denture teeth | Dental labs | — |
| Vintage Art Universal Gum | Ceramic stains adding 15 gum shades and 2 depth-adjusting materials to 29 crown shades | Dental labs | August 2025 |
| Vintage porcelain systems | Feldspathic and layering porcelain | Dental labs | — |
| Indirect composites (Ceramage line) | Lab-processed composite for crowns/veneers | Dental labs | — |
| Dental metals | Alloys for prosthetics | Dental labs | — |
Dental-related Business — Abrasives, polishing and preventive care
| Product | Description / capabilities | Target customer | Latest version / date |
|---|---|---|---|
| Abrasives and diamond/carbide burs | Grinding, cutting and finishing instruments — a historic domestic leadership category | Clinics and labs | — |
| Polishing systems | Composite and ceramic polishing discs, points and wheels | Clinics and labs | — |
| Merssage Pro One Paste / TT Plus / Stain Off | Renewed professional prophylaxis pastes with medicated ingredients | Dentists, hygienists | July 2025 |
| PTM Kit | Periodontal severity test kit, redesigned with 4 wells per tray (from 16) | Dentists | September 2025 renewal |
| Shaburio | Oral-function training device for elderly patients (lip, tongue and facial muscles) | Clinics treating oral hypofunction | September 2025 |
Dental-related Business — Orthodontics and implants
| Product | Description / capabilities | Target customer | Latest version / date |
|---|---|---|---|
| Genius Metal / Genius Crystal brackets | Metal and ceramic orthodontic brackets | Orthodontists | Existing; SHOFU Tube added December 2025 |
| SHOFU Tube | Molar tube bracket for second molars, sold alone or in kits | Orthodontists | December 2025 |
| EvenForce NT Closed Coil Spring | Low-force orthodontic spring to reduce patient discomfort | Orthodontists | December 2025 |
| Beauty Ortho Attachment | Resin material for aligner attachments | Orthodontists / aligner providers | September 2025 |
| Implant business (formerly SHOFU BIOFIX) | Sale of dental implant systems; folded into SHOFU INC. from 1 Oct 2026 to strengthen digital-dentistry system proposals | Dentists | Brand details n.d. |
Dental-related Business — Equipment and services
Machinery and instruments for clinics and labs, plus repair services (order backlog ¥494m at 31 March 2026). Third-party products are also distributed (e.g., ultrasonic scalers sourced from Nakanishi; paediatric crown products from Shinhung, per the Yuho cross-shareholding disclosures).
Nail-related Business
| Brand | Description | Target | Latest launches |
|---|---|---|---|
| PRESTO | Visible-light LED-cure gel nail system (flagship) | Professional nail artists | Molding Gel and Putty Gel colours (May 2025); Clean Bond Primer and Mag Plus top gels (Nov 2025); 48 new colours |
| ageha | Gel system co-developed with a well-known nail artist | Professionals | New art gels (Feb–Mar 2026); 32 new colours |
| ARTiS di Voce | Mid/low-price gel and hand-care system for Asian markets | Professionals in Asia (Taiwan focus) | 40 brush-on colours planned by Nail Labo Taiwan |
| by Nail Labo | At-home gel system | Consumers | Plump Top Gel (Nov 2025); 11 colours |
| NAIL DE DANCE | Acrylic nail system using dental-material technology | Professionals | New powders (May, Jul, Nov 2025) |
Other Businesses
Industrial rubber-bonded abrasives for hard ceramics and soft plastics, plus grinding/cutting materials, sold mainly into automotive mould-making (SHOFU Products Kyoto). FY2026 sales ¥99m.
Financial Narrative
Income statement
DPS note: reported pre-split DPS were ¥39 (FY2022, incl. ¥2 centenary), ¥57 (FY2023, incl. ¥10 centenary), ¥62 (FY2024); FY2025 ¥49 and FY2026 ¥60 (incl. ¥5 special) are post-split.
Margins (%; derived)
Revenue CAGR FY2022–FY2026: 9.2% (derived). Operating profit CAGR: 12.9%. Net profit CAGR: 17.7%.
EBITDA
S&P reports TTM EBITDA to June 2026 of ¥6.92bn.
Balance sheet
No goodwill is recorded on the consolidated balance sheet. Lease liabilities (IFRS 16 at overseas subsidiaries) are excluded from "total debt" above. At 30 June 2026 the company drew new long-term loans totalling ¥1,318m (¥325m current, ¥993m non-current), consistent with the debt-financed Shiga Shofu plant plan; net cash at that date was ¥11,224m. Investment securities at 31 March 2026 were ¥10,112m, of which listed cross-shareholdings were ¥7,938m (16.3% of net assets).
Cash flow
Sign convention: investing and financing flows shown negative as outflows. The Yuho's five-year table lists absolute values; the direction is confirmed by the detailed FY2025–FY2026 statements.
Ratios (derived unless stated)
ROIC methodology: NOPAT (operating profit × (1 − effective tax rate)) divided by operating invested capital (net assets + debt − cash − investment securities). S&P reports TTM ROIC of 14.5%.
Commentary on trends, inflections and drivers
Growth. FY2022–FY2025 delivered four consecutive years of double-digit growth driven by overseas expansion (overseas ratio up from 49.4% to 58.6%), CAD/CAM materials in Japan, and yen weakness that inflated translated overseas sales. FY2026 marked a clear inflection to low single-digit growth (+3.3%): Q1–Q3 cumulative sales grew only 0.9%, reflecting weaker demand for certain products in Japan and difficult overseas conditions (Middle East disruption in Europe; US tariff uncertainty). Q4 FY2026 (¥10,880m) and Q1 FY2027 (¥10,788m, +13.5%) indicate a re-acceleration.
Profitability. Operating margin expanded from 11.4% to 13.9% through FY2025 on gross-margin gains (+1.9pt to FY2025) and SG&A leverage, then dipped to 13.1% in FY2026 as SG&A rose 5.2% against 3.3% sales growth. Below the operating line, two recurring supports flatter earnings: (1) cross-shareholding sales (gains of ¥681m in FY2025, ¥836m in FY2026 and ¥1,124m in Q1 FY2027 alone), and (2) non-operating items (FX gains, ¥198m sale of stored goods in FY2026). FY2026 record net profit (+13.2%) therefore overstates underlying operating momentum (OP −3.1%).
Balance sheet. Exceptionally conservative: no financial debt at FY2025–FY2026 year-ends, equity ratio 84%, a retirement benefit asset (overfunded pension) of ¥2.46bn, and an unused ¥2bn commitment line. The capital-efficiency weakness is visible in ROE (10.7%) versus the 13.5% FY2028 target, driven by large cash and cross-holdings.
Working capital — the key red flag. Inventory rose from ¥7.6bn to ¥13.8bn (+82%) over four years while sales rose 42%; DIO went from 230 to 309 days. Management attributes the FY2026 increase mainly to merchandise and finished goods, consistent with building stock ahead of plant transitions and for overseas channels. This is why OCF has stagnated around ¥3.1–3.7bn despite net profit nearly doubling, and why FY2026 FCF turned negative once plant capex stepped up.
Capex cycle. FY2026 capex of ¥4.4bn (¥2.1bn on the Kyoto new plant) sits within the Fifth MTP's ¥9bn production-capacity envelope. The Kyoto head-office plant rebuild has a ¥4,091m budget (¥2,251m spent) completing August 2028; the Shiga Shofu new plant (¥1,370m, borrowed funds) is scheduled for December 2026.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | Contents | Main products | Operating entities |
|---|---|---|---|
Dental-related Business (デンタル関連事業) | Manufacture, sale and repair of dental materials and equipment | Artificial teeth, abrasives, metals, chemical products (restoratives, adhesives, CAD/CAM), cements, machinery & instruments | SHOFU INC., Shiga Shofu, SHOFU Products Kyoto, SHOFU BIOFIX (merged Oct 2026), SHOFU Dental Corp. (US), SHOFU Dental GmbH, Advanced Healthcare (UK), Merz Dental (DE), Digital Dental Services (DE), Shanghai and Changzhou manufacturing, Shanghai trading, Asia-Pacific (SG), India, Brazil, Vietnam, Middle East & Africa |
Nail-related Business (ネイル関連事業) | Gel and acrylic nail systems and equipment | PRESTO, ageha, ARTiS di Voce, by Nail Labo, NAIL DE DANCE | Nail Labo Co., Nail Labo Inc. (US), Taiwan Nail Labo (70%), Shiga Shofu (manufacture) |
Other Businesses (その他の事業) | Industrial abrasives derived from dental abrasive technology | Rubber-bonded abrasives for hard ceramics and soft plastics | SHOFU Products Kyoto |
Revenue by Segment and Segment Margins & Growth (%)
| Metric | FY2025 | FY2026 |
|---|---|---|
Dental net sales (JPY Mn) | 36,356 | 37,669 |
Nail net sales (JPY Mn) | 2,243 | 2,225 |
Other net sales (JPY Mn) | 98 | 99 |
Dental operating profit (JPY Mn) | 5,438 | 5,334 |
Nail operating profit (JPY Mn) | -67 | -113 |
Other operating profit (JPY Mn) | 14 | 0 |
Dental operating margin (%) | 15.0 | 14.2 |
Nail operating margin (%) | -3.0 | -5.1 |
Dental share of group sales (%) | 93.9 | 94.2 |
Nail share of group sales (%) | 5.8 | 5.6 |
Other share of group sales (%) | 0.3 | 0.2 |
Revenue by Segment and Segment Margins & Growth (%) (Quarterly)
| Metric | Q1 FY2026 | Q1 FY2027 |
|---|---|---|
Dental net sales (JPY Mn) | 8,965 | 10,247 |
Nail net sales (JPY Mn) | 518 | 516 |
Other net sales (JPY Mn) | 22 | 25 |
Dental segment profit (JPY Mn) | 1,535 | 2,004 |
Nail segment profit (JPY Mn) | -42 | -61 |
Other segment profit (JPY Mn) | 0 | -1 |
Dental segment margin (%) | 17.1 | 19.6 |
Income Statement and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Net sales (JPY Mn) | 28,137 | 31,678 | 35,080 | 38,698 | 39,994 |
Revenue growth (%) | 14.0 | 12.6 | 10.7 | 10.3 | 3.3 |
Gross profit (JPY Mn) | 16,167 | 18,699 | 20,996 | 22,992 | 23,741 |
SG&A incl. R&D (JPY Mn) | 12,950 | 14,874 | 16,286 | 17,599 | 18,513 |
Operating profit (JPY Mn) | 3,217 | 3,824 | 4,709 | 5,392 | 5,226 |
Ordinary profit (JPY Mn) | 3,658 | 4,238 | 5,118 | 5,523 | 5,859 |
Pre-tax profit (JPY Mn) | 3,609 | 4,409 | 5,280 | 6,154 | 6,590 |
Net profit attributable to owners (JPY Mn) | 2,546 | 3,135 | 3,655 | 4,317 | 4,887 |
Comprehensive income (JPY Mn) | 3,366 | 3,584 | 7,157 | 2,471 | 7,744 |
EPS basic (JPY, split-adjusted) | 71.61 | 88.05 | 103.09 | 121.52 | 137.38 |
EPS diluted (JPY, split-adjusted) | 71.17 | 87.56 | 102.62 | 121.09 | 136.97 |
DPS (JPY, split-adjusted) | 19.5 | 28.5 | 31 | 49 | 60 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansMargin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Gross margin (%) | 57.5 | 59.0 | 59.9 | 59.4 | 59.4 |
SG&A ratio (%) | 46.0 | 47.0 | 46.4 | 45.5 | 46.3 |
Operating margin (%) | 11.4 | 12.1 | 13.4 | 13.9 | 13.1 |
Ordinary margin (%) | 13.0 | 13.4 | 14.6 | 14.3 | 14.6 |
Net margin (%) | 9.0 | 9.9 | 10.4 | 11.2 | 12.2 |
Income Statement and Margin Analysis (%) (FY2025–FY2026)
| Metric | FY2025 | FY2026 |
|---|---|---|
Depreciation & amortisation (JPY Mn) | 1,059 | 1,210 |
EBITDA (JPY Mn) | 6,451 | 6,436 |
EBITDA margin (%) | 16.7 | 16.1 |
Liquidity & Coverage Ratios and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets (JPY Mn) | 40,709 | 43,727 | 50,093 | 49,994 | 57,706 |
Cash and deposits (JPY Mn) | 9,064 | 9,578 | 9,716 | 10,653 | 10,121 |
Inventories (JPY Mn) | 7,554 | 8,391 | 10,290 | 11,583 | 13,765 |
Short-term debt incl. current LTD (JPY Mn) | 325 | 907 | 281 | 0 | 0 |
Long-term debt (JPY Mn) | 1,153 | 281 | 0 | 0 | 0 |
Total debt (JPY Mn) | 1,478 | 1,188 | 281 | 0 | 0 |
Net cash incl. short-term investments (JPY Mn) | 7,586 | 8,390 | 9,435 | 10,892 | 10,264 |
Net assets (JPY Mn) | 32,940 | 35,515 | 41,609 | 42,736 | 48,689 |
Intangible assets (JPY Mn) | 427 | 462 | 524 | 556 | 619 |
Working capital (JPY Mn) | 16,025 | 16,271 | 19,586 | 22,303 | 23,550 |
Book value per share (JPY) | 920.77 | 998.32 | 1,168.02 | 1,198.37 | 1,363.94 |
Equity ratio (%) | 80.5 | 80.8 | 82.7 | 85.2 | 84.1 |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow (JPY Mn) | 3,736 | 3,170 | 3,089 | 3,447 | 3,371 |
Investing cash flow (JPY Mn) | -1,288 | -1,290 | -1,295 | -914 | -2,070 |
Financing cash flow (JPY Mn) | -1,074 | -1,457 | -2,096 | -1,783 | -1,968 |
Cash & equivalents at year end (JPY Mn) | 8,208 | 8,830 | 9,024 | 10,061 | 9,774 |
Cash Flow (FY2025–FY2026)
| Metric | FY2025 | FY2026 |
|---|---|---|
Purchase of PP&E (JPY Mn) | 1,229 | 3,433 |
Purchase of intangibles (JPY Mn) | 88 | 169 |
Free cash flow, OCF less PP&E (JPY Mn) | 2,218 | -62 |
Dividends paid (JPY Mn) | 1,385 | 1,849 |
Share buybacks (JPY Mn) | 0 | 0 |
Proceeds from sale of investment securities (JPY Mn) | 869 | 1,124 |
Total capex, accrual basis (JPY Mn) | — | 4,413 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE, company-reported (%) | 8.1 | 9.2 | 9.5 | 10.3 | 10.7 |
ROA, net profit / avg. assets (%) | 6.5 | 7.4 | 7.8 | 8.6 | 9.1 |
Current ratio (x) | 4.61 | 3.74 | 4.50 | 5.27 | 4.74 |
Debt / equity (x) | 0.045 | 0.033 | 0.007 | 0.000 | 0.000 |
Interest coverage, OP / interest expense (x) | 268 | 212 | 214 | 317 | 327 |
Asset turnover (x) | 0.72 | 0.75 | 0.75 | 0.77 | 0.74 |
Days sales outstanding | 42.6 | 40.0 | 47.1 | 39.2 | 42.0 |
Days inventory outstanding | 230.3 | 236.0 | 266.7 | 269.2 | 309.1 |
Days payables outstanding | 28.3 | 28.4 | 35.7 | 28.6 | 29.1 |
Cash conversion cycle (days) | 244.6 | 247.6 | 278.1 | 279.8 | 322.0 |
Consolidated payout ratio (%) | 27.2 | 32.4 | 30.1 | 40.3 | 43.7 |
Financial Ratios (x) and Margin Analysis (%)
| Metric | FY2025 | FY2026 |
|---|---|---|
Net debt / EBITDA (x) | -1.69 | -1.59 |
ROIC, operating (%) | 16.4 | 13.7 |
Effective tax rate (%) | 29.6 | 25.7 |
Revenue by Region and Revenue by Region (%)
| Region | FY2022 | FY2023 | FY2024 |
|---|---|---|---|
Japan (JPY Mn) | 14,233 | 15,025 | 15,588 |
Europe (JPY Mn) | 5,659 | 6,355 | 7,492 |
Asia & Oceania (JPY Mn) | 4,919 | 6,389 | 7,758 |
North & Latin America (JPY Mn) | 3,325 | 3,908 | 4,241 |
Overseas ratio (%) | 49.4 | 52.6 | 55.6 |
Country / Region Details
| Country / region | FY2025 |
|---|---|
Japan (JPY Mn) | 16,011 |
China (JPY Mn) | 5,689 |
United States (JPY Mn) | 4,271 |
Germany (JPY Mn) | 3,883 |
Other countries (JPY Mn) | 8,843 |
Overseas ratio (%) | 58.6 |
Region Overview
| Region | FY2026 |
|---|---|
Japan (JPY Mn, derived) | 17,112 |
North & Latin America (JPY Mn) | 5,103 |
Europe (JPY Mn) | 8,658 |
Asia (JPY Mn) | 9,121 |
Revenue by Region
| Region | Q1 FY2026 | Q1 FY2027 |
|---|---|---|
Japan (JPY Mn) | 4,142 | 4,620 |
North & Latin America (JPY Mn) | 1,224 | 1,407 |
Europe (JPY Mn) | 1,950 | 2,315 |
Asia (JPY Mn) | 2,189 | 2,445 |
Segment / Region Details
| Segment / region | Q1 FY2027 |
|---|---|
Dental — Japan | 4,291 |
Dental — Americas | 1,377 |
Dental — Europe | 2,315 |
Dental — Asia | 2,262 |
Nail — Japan | 303 |
Nail — Americas | 30 |
Nail — Asia | 182 |
Other — Japan | 25 |
Group Entities
| Subsidiary | Net sales FY2026 (JPY Mn) | Ordinary profit (JPY Mn) | Ordinary margin (%) |
|---|---|---|---|
Shofu Dental Trading (Shanghai) | 6,043 | 1,284 | 21.2 |
SHOFU Dental Corp. (US) | 4,832 | 669 | 13.8 |
SHOFU Dental GmbH (Germany) | 4,621 | 771 | 16.7 |
Per-Share Data and Valuation Multiples (x)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Fiscal year-end implied price (JPY, PER × EPS, split-adjusted) | 781 | 1,013 | 1,464 | 2,114 | 1,676 |
Year-end P/E (x) | 10.9 | 11.5 | 14.2 | 17.4 | 12.2 |
SHOFU 5-year TSR index (Mar 2021 = 100) | 80.6 | 107.1 | 156.0 | 225.7 | 187.9 |
TOPIX incl. dividends index (Mar 2021 = 100) | 102.0 | 107.9 | 152.5 | 150.2 | 202.2 |
Valuation Multiples
| Multiple | SHOFU | Basis |
|---|---|---|
P/E (trailing, TTM EPS ¥173.12 incl. securities gains) | 13.0x | S&P TTM to Jun 2026 |
P/E (forward, company FY2027 EPS ¥133.66) | 16.9x | Company guidance |
P/B | 1.57x | BVPS ¥1,433.31 at 30 Jun 2026 |
EV/Sales (TTM sales ¥41.28bn) | 1.68x | EV ≈ ¥69.2bn |
EV/EBITDA (TTM EBITDA ¥6.92bn) | 10.0x | — |
Dividend yield (FY2027 forecast ¥67) | 3.0% | — |
Nakanishi P/E (peer reference) | ≈23x | finboard.jp, date of snapshot n.d. |
Per-Share Data and Capital Markets Data (JPY)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 | FY2027 |
|---|---|---|---|---|---|---|
DPS (JPY, split-adjusted; FY2027 = forecast) | 19.5 | 28.5 | 31 | 49 | 60 | 67 |
Of which special/commemorative (JPY, split-adjusted) | 1 | 5 | 0 | 0 | 5 | 12 |
Bucket Details
| Bucket | Amount (JPY Mn) |
|---|---|
Due within 1 year (current portion of long-term loans) | 325 |
Due after 1 year (long-term loans) | 993 |
Total borrowings | 1,318 |
Undrawn committed credit lines | 2,000 |
Analyst Conclusions
Management guidance
FY2027: net sales ¥42,958m (+7.4%), operating profit ¥6,003m (+14.9%, margin 14.0%), ordinary profit ¥5,890m (+0.5%), net profit ¥4,756m (−2.7%), DPS ¥67. Q1 FY2027 delivered 25.1% of full-year sales guidance and 32.4% of OP guidance; H1 OP guidance of ¥2,949m implies Q2 OP of only ~¥1.0bn, which appears conservative. The H1 net-profit guidance (¥2,552m) is already 84% achieved after Q1. Guidance was not revised at Q1 despite the beat, suggesting an upgrade at H1 is plausible. Fifth MTP target (FY2028): sales ¥50.1bn, OP ¥7.5bn, ROE 13.5%.
Consensus expectations
Consensus sits close to guidance for FY2027 (sales +7%, OP +14%), with a three-year revenue CAGR around 7%. At that pace, FY2028 sales would land around ¥46bn — short of the ¥50.1bn MTP target without acquisitions or significant FX help.
Bull case
-
Operating re-acceleration is real: Q1 FY2027 dental sales +14.3% and dental margin 19.6% indicate FY2026 was a temporary air pocket; full-year OP could exceed ¥6.5bn versus ¥6.0bn guidance.
-
Capital efficiency catalysts: cross-shareholdings (¥7.9bn) and net cash (¥11.2bn) together equal ~24% of market cap; continued disposals, rising payouts (FY2027 implied 50%) and an engaged shareholder (Neuberger Berman at 5.64%) could lift ROE toward 13.5% and support a P/B re-rating.
-
M&A-driven scale-up: Vision10 explicitly requires non-organic growth; the debt-free balance sheet and Mitsui Chemicals backing give SHOFU firepower for accretive bolt-ons in digital dentistry, prevention and orthodontics.
Bear case
-
China and FX: the most profitable overseas subsidiary (Shanghai) showed declining sales in Q1 FY2027; any yen strength would erode translated sales that are now ~59% of the total.
-
Earnings quality and cash conversion: net-profit growth relies on securities gains (¥836m FY2026; ¥1,124m Q1 FY2027) and FY2026 FCF was negative; inventory at 309 days raises obsolescence and working-capital risk.
-
Credibility of long-range targets: the ¥50bn vision has been deferred three times; Vision10's ¥250bn (6x scale-up) target may lead to over-priced acquisitions, while SG&A intensity limits organic margin expansion toward 20%.
Key catalysts and monitorables (next 12 months)
-
Q2 FY2027 results (expected early November 2026): potential guidance upgrade; China trajectory.
-
Integration of the implant business post-1 October 2026 and any digital-dentistry bundle launches.
-
Shiga Shofu plant completion (December 2026) and Kyoto plant progress; capex versus FCF.
-
Inventory trend (DIO) and operating cash flow.
-
Further cross-shareholding sales and special dividends; possible first buyback.
-
Any M&A announcement under Vision10.
-
New Fifth MTP progress update and FY2028 guidance (May 2027); possible Sixth MTP framing.
-
Board effectiveness after the June 2026 overhaul; investor engagement by Neuberger Berman.
-
Yen/USD/EUR/CNY exchange rates; Japan dental reimbursement revisions.
Analyst verdict
SHOFU is a high-quality, conservatively financed niche franchise caught between two identities: a century-old Japanese prosthetics and abrasives leader, and an aspiring global digital-dentistry platform. The financial record over FY2022–FY2026 is genuinely strong — revenue compounded at about 9%, net profit at about 18%, and ROE climbed from 8.1% to 10.7% — but FY2026 exposed the fragility beneath the headline records. Operating profit fell, net-profit growth leaned on cross-shareholding sales, inventories swelled to more than ten months of cost of sales, and capex pushed free cash flow below zero.
The first quarter of FY2027 materially improves the picture. Double-digit growth across every region by company location, a dental segment margin near 20%, and a raised dividend show that the operating engine has re-engaged. The new governance structure — a CEO/CFO model, a Sysmex CFO as independent director, and the end of the chairman role — signals more market-oriented management at a point where an engagement investor has built a 5.6% stake.
Valuation is undemanding rather than cheap: roughly 10x EV/EBITDA and 17x forward P/E on guidance that looks conservative, with about a quarter of the market capitalisation backed by net cash and listed securities. The principal swing factors are China, the yen, and whether management can convert excess capital into either higher returns or sensible acquisitions.
On balance, SHOFU merits a constructive but selective stance: the near-term set-up (likely guidance upgrade, rising payouts, continued unwinding of cross-holdings) is favourable, while the long-term thesis depends on disciplined execution of Vision10. Investors should demand evidence of inventory normalisation and positive free cash flow by FY2028, and should treat any large acquisition as the key test of capital discipline. Until then, SHOFU is best viewed as a steady compounder with optional upside from capital-policy reform rather than a transformational growth story.
Derived figures are arithmetic computations from disclosed data and should be checked against primary filings before use in investment decisions. This document is not investment advice.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Title | Born (age) | Board since | Background | Independent |
|---|---|---|---|---|---|
Tetsuo Takami (髙見哲夫) | Representative Director, President & CEO | Jun 1960 (66) | 2020 | Joined 1983; Sales Dept head 2012; Tokyo Branch GM 2015; Managing EO Sales 2019; President since Jun 2022; CEO title added Jun 2026 | No |
Takahiro Umeda (梅田隆宏) | Representative Director, Executive VP & CFO (Finance, Nail business) | Feb 1960 (66) | 2023 | Bank of Kyoto branch manager; joined 2015 as Finance head | No |
Hideji Sonoi (薗井秀次) | Director, Managing EO (Production) | Mar 1971 (55) | 2024 | Joined 1995; Executive Director of Merz Dental 2018 | No |
Ryuichi Yoshimoto (吉本龍一) | Director, Managing EO (R&D, Technology, Marketing) | Aug 1964 (62) | 2026 | Joined 1988; Technology head 2014; R&D head 2018 | No |
Hiroyoshi Miyake (三宅宏善) | Director, Managing EO (General Affairs, IT) | Apr 1967 (59) | 2026 | Joined 1990; Corporate Planning head 2020; outside director of Sun Medical | No |
Daizo Nishimura (西村大三) | Outside Director; chairs Nomination & Remuneration Council | May 1959 (67) | 2020 | CPA/tax accountant; representative partner, Otemae Audit Corporation | Yes |
Junko Yaguchi (矢口順子) | Outside Director | Apr 1963 (63) | 2025 | Salomon Brothers, Merrill Lynch, BNP Paribas; director of MINKABU THE INFONOID | Yes |
Kensuke Iizuka (飯塚健介) | Outside Director | Mar 1970 (56) | 2026 | Sysmex Corporation Managing EO and CFO | Yes |
Shingo Ono (小野真吾) | Outside Director | Feb 1976 (50) | 2026 | Mitsui Chemicals; GM Oral Care Business; former Kulzer GmbH supervisory board member | No (major shareholder executive) |
Directors' Remuneration
| Category | Total (JPY Mn) | Fixed | Performance bonus | Restricted stock | Headcount |
|---|---|---|---|---|---|
Inside directors | 269 | 164 | 48 | 56 | 5 |
Inside auditors | 38 | 38 | 0 | 0 | 2 |
Outside officers | 42 | 42 | 0 | 0 | 8 |
Board & Management Changes
| Date | Change |
|---|---|
Jun 2025 | Junko Yaguchi and Kaori Matsue (Mitsui Chemicals) join as outside directors; Mitsuo Kamimoto and Hiromi Hayashida retire |
Apr 2026 | Umeda's portfolio expanded to include IT |
13 May 2026 | Leadership transition announced: CEO/CFO titles introduced, "generational change" in governance |
24 Jun 2026 | Negoro (Chairman), Yamazaki (moves to EVP/CSO off-board), Suzuki and Matsue (outside) leave the board; Yoshimoto, Miyake, Iizuka and Ono join; EVP Kazuhiko Murakami (Sales & International) leaves the executive roster; auditor Shigeyuki Komatsu retires |
Major Shareholders
| Rank | Shareholder | Shares (thousand) | % of outstanding |
|---|---|---|---|
| 1 | Mitsui Chemicals, Inc. | 7,160 | 20.11 |
| 2 | The Master Trust Bank of Japan (trust account) | 2,451 | 6.88 |
| 3 | The Bank of Kyoto | 1,424 | 4.00 |
| 4 | Nippon Life Insurance | 1,292 | 3.63 |
| 5 | The Shiga Bank | 1,204 | 3.38 |
| 6 | Northern Trust Co. (AVFC) re IEDP AIF Clients | 896 | 2.51 |
| 7 | SHOFU Employee Shareholding Association | 496 | 1.39 |
| 8 | Government of Norway | 475 | 1.33 |
| 9 | BBH for Neuberger Berman Japan Equity Engagement Fund | 460 | 1.29 |
| 10 | J. Morita Corporation | 457 | 1.28 |
Competitive Landscape
Key Competitors
| Competitor | HQ / status | Overlap with SHOFU |
|---|---|---|
Dentsply Sirona | US, NASDAQ | Restoratives, CAD/CAM, prosthetics, artificial teeth, abrasives |
Envista (Kerr, Nobel Biocare) | US, NYSE | Restoratives, adhesives, polishing, implants |
Ivoclar Vivadent | Liechtenstein, private | Composites, ceramics, CAD/CAM, artificial teeth |
GC Corporation | Japan, private | Glass ionomers, composites, CAD/CAM, prosthetics — closest domestic rival |
Kuraray Noritake Dental | Japan, subsidiary of Kuraray | Adhesives, zirconia (Katana), composites |
Solventum (formerly 3M Health Care) | US, NYSE | Restoratives, adhesives, CAD/CAM, orthodontics |
Kulzer (Mitsui Chemicals) | Germany, subsidiary of Mitsui Chemicals | Composites, denture teeth, lab materials — also an alliance-adjacent party |
Tokuyama Dental | Japan, subsidiary of Tokuyama Corp. | Composites, adhesives |
VOCO GmbH | Germany, private | Composites, cements |
Coltene Holding | Switzerland, SIX | Restoratives, endodontics, rotary instruments |
Nakanishi Inc. | Japan, TSE Prime 7716 | Rotary instruments and equipment (also a partner and cross-shareholding) |
Straumann Group | Switzerland, SIX | Implants, CAD/CAM, clear aligners (relevant to SHOFU's implant/digital ambitions) |
Peer Comparison FY2024
| Company | Revenue | Revenue growth | Operating margin | R&D intensity | Source / period |
|---|---|---|---|---|---|
SHOFU | ¥40.0bn | +3.3% | 13.1% | 5.4% | Yuho, FY3/2026 |
Nakanishi | ¥81.2bn | +5.4% | 17.4% | — | Company results, FY12/2025 (net loss of ¥2.4bn due to ¥13.7bn impairment) |
Dentsply Sirona | ≈US$3.8bn | Declining (n.d. precise) | — | — | FY2024 company report |
Envista | ≈US$2.5bn | — | — | — | FY2024 company report |
Straumann | ≈CHF 2.5bn | — | — | — | FY2024 company report |
Recent Developments
--



